

Applicant : Ilya Trakht et al.
Serial No.: 09/664,958
Filed: September 18, 2000
Page 32

C28
w

administering to a subject diagnosed with the cancer an antibody directed to an epitope on TIP-2 antigen or an Fab fragment thereof, which epitope is recognized by monoclonal antibody 27.B1 produced by the hybridoma designated PTA-1599, said antibody/Fab fragment being detectably labeled, under appropriate conditions to bind the antibody to TIP-2 antigen on the surface of any cells in the subject; (b) determining quantity of detectably labeled antibody 27.B1/Fab fragment bound to the surface of cells in the subject according to the instant method; and (c) comparing the quantity of detectably labeled antibody 27.B1/Fab fragment bound to cells in step (b) with the presence of detectably labeled antibody 27.B1 bound to cells at (i) diagnosis time or (ii) after treatment, wherein a greater quantity of detectably labeled antibody 27.B1/Fab fragment bound to cells in step (b) than at (i) diagnosis time or (ii) after treatment, indicates progression of the cancer in the subject and a lesser quantity of detectably labeled antibody 27.B1/Fab fragment bound to cells in step (b) than at (i) diagnosis time or (ii) after treatment indicates regression of the cancer in the subject.

On pages 102-129, please delete the paragraphs between page 102, line 34 and page 129, line 20.

In the Claims:

Please amend claims 6 and 16 as indicated below. A marked-up copy of the amended claims is attached hereto as **Exhibit B**.

- D11
C29
-
6. (Amended) The monoclonal antibody of claim 1 which binds to the same domain of TIP-2 as does monoclonal antibody 27.B1.
-